SkyOak Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

SkyOak Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$310K	Sell	9,873 -2,359	-19%	-$69.6K	0.05%	180
2026 Q1	$303K	Buy	+12,232	New	+$291K	0.06%	178

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SkyOak Wealth's CPRX Position: Q2 2026 in Review

SkyOak Wealth reduced its Catalyst Pharmaceutical (CPRX) stake by 19% in Q2 2026, selling an estimated $69.6K and leaving 9,873 shares worth $310K. The position accounts for 0.05% of the portfolio, ranked #180.

SkyOak Wealth first reported a position in CPRX in Q1 2026 and has held it in 2 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

SkyOak Wealth held 9,873 shares of Catalyst Pharmaceutical worth $310K as of Q2 2026.
SkyOak Wealth sold 2,359 Catalyst Pharmaceutical shares in Q2 2026, an estimated $69.6K.
Catalyst Pharmaceutical made up 0.05% of SkyOak Wealth's portfolio in Q2 2026, its #180 holding.
SkyOak Wealth first reported a position in Catalyst Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on SkyOak Wealth's 13F filing for Q2 2026, filed 30 Jul 2026.